While every fledgling company hopes to follow in the footsteps of its successful forebears, Inhibitex Inc. hopes to actually mimic the footsteps of its role models.

In developing its MSCRAMMs to treat bacterial and fungal infections, the company's model is MedImmune Inc. - starting with a polyclonal antibody for a given indication and subsequently developing a monoclonal antibody to replace the original product. In the marketing arena, Inhibitex will position its products as adjuncts to antibiotics, essentially forming cocktail regimens, as has become the standard in treating HIV infection/AIDS.